Abstract: Cultures of Delftia bacteria are disclosed. Antimicrobial agents derived therefrom are also disclosed.

Abstract: The invention discloses compositions comprising bisdemethoxycurcumin and methods for managing polycystic ovary syndrome (PCOS) and its associated conditions which include hormonal imbalance, obesity, hypothyroidism, hyperandrogenism, oxidative stress, inflammation, gut dysbiosis, hypercholesterolemia, cardiovascular complications, hyperglycemia and insulin resistance. The invention also discloses the potential of a curcuminoid composition comprising 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin for use in the therapeutic management of PCOS.

Abstract: There is provided a system, installed on a vehicle or trailer, for performing an agricultural task. The system comprises a platform connecting to the vehicle or trailer and comprising a socket for an accessory. A plurality of accessories is provided, wherein one accessory is selected among them for installation in the accessory socket. A vision system is operatively connected to a computer and collects data of the environment about the accessory, the computer using the collected data to determine an instruction for performing the agricultural task and to send the instruction to the accessory installed in the accessory socket to perform the agricultural task. The accessory is interchangeable in the accessory socket depending on the agricultural task. The box handling stage and pallet mounting stage can be robotized for efficient automation.

Abstract: The present invention provides topologies of phase-controlled IGBT bridge type and GTO bridge type Fault Current Limiter (FCL), which allow the precise limitation of fault currents to the desired values and can keep these values constant despite variations (dynamic behavior) of the fault currents. According to an embodiment of the invention, the topologies enable to use a phase control approach for optimal firing angles calculation. This control approach can be used in the proposed FCL topologies and other controlled bridge topologies such as SCRs bridge, GTO bridge, and IGBT/IGCT/Mosfet bridge topologies.

Abstract: A composition enriched with bisdemethoxycurcumin standardized to contain 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin. More specifically the invention discloses the potential of a composition comprising 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin in the management of nephrotoxicity in mammals. The composition further comprises a Nigella sativa extract standardised to contain not less than 2% w/w thymoquinone and about 0.01%-10% w/w thymohydroquinone.

Abstract: There is provided a method for reconstructing a 3D image, comprising: obtaining Doppler ultrasound images depicting a blood vessel and measurement of blood flow in the blood vessel, and 2D camera images captured by a camera depicting fiducial objects randomly distributed within a viscous material and spaced apart by random distances on a surface of the individual, computing 3D coordinates within a world coordinate system for pixels of the Doppler images using an external reference of an ultrasound transducer pose computed by analysis of relative changes in locations of the fiducial objects within sequential camera images, and computing a respective estimated blood flow for pixels of the Doppler images at locations within the blood vessel, reconstructing a 3D image from 3D voxels computed from the 3D coordinates of pixels of the Doppler images, including respective estimated blood flow, wherein the 3D image depicts the blood vessel and blood flow.

Abstract: The invention discloses compositions and methods comprising enriched Bisdemethoxycurcumin (BDMC) present not less than 20% w/w for use in inhibiting Receptor for Advanced Glycation End-Products (RAGE) expression in a subject with chronic-inflammatory condition. The composition further comprises ?-amyrin palmitate (BAP). The invention also includes disclose the use of the above composition in the management of chronic inflammatory condition in a subject.

Abstract: The invention discloses a composition comprising not less than 20% w/w bisdemethoxycurcumin for regeneration of alveolar cells damaged in emphysematous conditions and for the therapeutic management of chronic obstructive pulmonary disease and acute respiratory distress syndrome. The composition further comprises 10-35% w/w demethoxycurcumin and 10-45% w/w curcumin. The composition is very suitable for treating COPD and ARDS due to viral infections, specifically COVID 19 and for improving lung function during prognosis.

Abstract: Disclosed are the skin care applications of a composition containing the partially purified extracellular metabolite isolated from Bacillus coagulans MTCC 5856. More specifically, the invention discloses the ability of the partially purified extracellular metabolite isolated from Bacillus coagulans MTCC 5856 to confer protection to the skin fibroblasts against UV induced cell damage and apoptosis, oxidative stress and inflammation.

Abstract: A ski pole holder is provided. The ski pole holder is positioned toward a toe side of a ski footwear, to secure a portion of the ski pole within a channel of the ski pole holder. The ski pole holder includes a housing with the channel that extends towards the skier. When the skier is riding a ski lift, the ski pole is received within the housing to retain the ski pole. Fasteners within the channel secure the ski pole to the ski pole holder. The housing also includes a front sidewall and guides to help ensure that the tip of the ski pole is easily positioned within the channel. A lateral sidewall includes an open slot to provide for removal of snow that accumulates within the channel. The ski pole holder is attachable to the upper side of the ski footwear or is permanently integrated.

Abstract: The present invention discloses a method for therapeutic management of pulmonary fibrosis in mammals using a composition comprising iso-garcinol or octahydrocurcumin or a combination of iso-garcinol and octahydrocurcumin. The composition is very suitable for treating pulmonary fibrosis due to viral infections, specifically COVID 19 and for improving lung function during prognosis.

Abstract: The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of metabolic syndrome in mammals.

Abstract: The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of interstitial lung disease or lung fibrosis.

Abstract: Disclosed are the uses of compositions containing not less than 10% w/w of Oroxylin A, not less than 10% w/w of Baicalein and not less than 2% w/w of Chrysin in inhibiting the activity and expression of ? secretase. The invention also discloses the reduction of amyloid content in PS-70 cells using the abovementioned composition. Further, the invention mentions the use of the composition for the therapeutic management of ? secretase mediated disorders.

Abstract: The present invention discloses the potential of probiotic bacteria Bacillus coagulans individually or in combination with multi-enzyme complex for reducing gluten content in foods rich in gluten and for the increased utilization of gluten. The invention further discloses a method for the management of gluten intolerance using composition comprising Bacillus coagulans and multi-enzyme complex in mammals.

Abstract: The present invention discloses a method for therapeutic management of atrophic gastritis and colitis using a composition comprising Bacillus coagulans MTCC 5856 individually or in combination with anthocyanins. The invention further discloses a method for preventing neoplastic transformation of mucosal cells in gastro-intestinal tract and improving gut barrier function in mammals using a composition comprising Bacillus coagulans MTCC 5856 individually or in combination with anthocyanins.

Abstract: The present invention discloses a method for protecting mammalian skin against the harmful effects of UV radiation and environmental pollutants, using one or plant actives selected from group comprising a composition comprising not less than 10% w/w oroxylin A, not less than 10% w/w baicalein and not less than 2% w/w chrysin; 95% w/w oxyresveratrol; 95% w/w tetrahydrocurcumin; 90% w/w pterostilbene and a composition comprising at least 10% w/w ?-glucogallin and at least 10% w/w total mucic acid gallates. The invention also discloses a method for cleansing and rejuvenating mammalian skin, exposed to environmental pollutants and UV radiation using the aforesaid plant actives.

Abstract: A probiotic-alcoholic beverage composition comprising Bacillus coagulans is disclosed herein wherein the said spore or vegetative cell of Bacillus coagulans exhibited high recovery, tolerability, compatibility and viability of spores and vegetative cells after brewing. Methods for brewing an alcoholic beverage composition comprising Bacillus coagulans wherein said spore or bacterium is added during pre-fermentation, during fermentation and post fermentation stages are also disclosed.

Abstract: The present invention discloses a novel fructophilic lactic acid producing bacteria Bacillus coagulans strain FF-7 (MTCC 25235) and the process of isolation and characterization of the bacteria.

Abstract: The present invention discloses a composition comprising heat inactivated spores and/or comprising heat inactivated vegetative cells of probiotic bacteria Bacillus coagulans, and a process for preparing the same. The invention also discloses a method of modulating immune function in mammals by activating macrophages, using a composition comprising Bacillus coagulans in the form of live or heat inactivated spore and/or vegetative cells.